DDInter150 DDInter131
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
Azathioprine {u} (Compound) resembles {v} (Compound) Adenine
Azathioprine {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
Azathioprine {u} (Compound) binds {v} (Gene) GSTA1
Azathioprine {u} (Compound) upregulates {v} (Gene) NUCB2
Azathioprine {u} (Compound) is included by {v} (Pharmacologic Class) Purines
Azathioprine {u} (Compound) downregulates {v} (Gene) STUB1
Azathioprine {u} (Compound) causes {v} (Side Effect) Hodgkin's disease
Azathioprine (Compound) resembles Adenine (Compound)
Azathioprine (Compound) treats systemic lupus erythematosus (Disease)
Azathioprine (Compound) binds GSTA1 (Gene)
Azathioprine (Compound) upregulates NUCB2 (Gene)
Azathioprine (Compound) is included by Purines (Pharmacologic Class)
Azathioprine (Compound) downregulates STUB1 (Gene)
Azathioprine (Compound) causes Hodgkin's disease (Side Effect)